Bayer AG - Stockholders' Newsletter First Quarter 2007

Special Interest

Investor Relations

Press

Jobs and Career

Culture

General Conditions of Use Privacy Statement Imprint Technical Details

Jump in HealthCare sales and earnings - Bayer: excellent start to 2007

News

Nexavar® extends overall survival in patients with liver cancer
The cancer medicine Nexavar®, jointly developed by Bayer HealthCare and Onyx Pharmaceuticals, is also showing promising study results in liver cancer. » more

BayArena to be enlarged
The BayArena, the stadium that is home to the Bundesliga soccer team Bayer 04 Leverkusen, is to be modernized, enlarged and its capacity increased to accommodate over 30,000 spectators. » more

Bayer CropScience targets growth in China
Bayer CropScience is aiming for growth in China. The company plans to increase annual sales in the People’s Republic from the current level of €65 million (2006) to over €100 million in the medium term. » more

New study data on treatment of multiple sclerosis with Betaferon®/Betaseron®
According to new data recently announced by Bayer Schering Pharma, immediate initiation of Betaferon®/Betaseron® (interferon beta-1b) treatment in patients with a first event suggestive of multiple sclerosis (MS) can significantly reduce the risk of permanent neurological impairment as measured by the Expanded Disability Status Scale (EDSS) by 40 percent » more

News Overview

Bayer Group
Key Data
Net Sales, EBITDA, EBIT, Net income, Cash flow, Non-operating result, Number of Employees » more

Bayer Stock
Key Data
Bayer stock performed very well in the first quarter of 2007. » more

Management Report
Overview of Sales, Earnings and Financial Position
Bayer got off to an excellent start in 2007, substantially improving on its strong performance in the prior-year quarter. » more